Acrivon Therapeutics Inc (NASDAQ: ACRV) is -72.76% lower on its value in year-to-date trading and has touched a low of $1.30 and a high of $10.29 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ACRV stock was last observed hovering at around $1.99 in the last trading session, with the day’s loss setting it -0.35%.
Currently trading at $1.64, the stock is -6.90% and -57.18% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 16.04 million and changing -17.59% at the moment leaves the stock -74.46% off its SMA200. ACRV registered -83.30% loss for a year compared to 6-month loss of -79.63%. The firm has a 50-day simple moving average (SMA 50) of $3.83 and a 200-day simple moving average (SMA200) of $6.4206.
The stock witnessed a -37.16% gain in the last 1 month and extending the period to 3 months gives it a -69.91%, and is -9.39% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 14.67% over the week and 19.38% over the month.
Acrivon Therapeutics Inc (ACRV) has around 78 employees, a market worth around $51.42M and $0.00M in sales. Distance from 52-week low is 26.15% and -84.06% from its 52-week high. The company has generated returns on investments over the last 12 months (-44.91%).
The EPS is expected to shrink by -12.13% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
Acrivon Therapeutics Inc (ACRV) Top Institutional Holders
90.0 institutions hold shares in Acrivon Therapeutics Inc (ACRV), with institutional investors hold 95.36% of the company’s shares. The shares outstanding are 31.23M, and float is at 21.74M with Short Float at 3.27%. Institutions hold 74.43% of the Float.
The top institutional shareholder in the company is RA CAPITAL MANAGEMENT, L.P. with over 8.34 million shares valued at $48.37 million. The investor’s holdings represent 23.083% of the ACRV Shares outstanding. As of 2024-06-30, the second largest holder is PERCEPTIVE ADVISORS LLC with 5.36 million shares valued at $31.09 million to account for 14.8366 of the shares outstanding. The other top investors are SANDS CAPITAL VENTURES, LLC which holds 2.12 million shares representing 5.8745% and valued at over $12.31 million, while CITADEL ADVISORS LLC holds 5.8663 of the shares totaling 2.12 million with a market value of $12.29 million.
Acrivon Therapeutics Inc (ACRV) Insider Activity
#####
